Protocol Ledger

NCT04781114 · Phase III · COMPLETED

The Safety and Efficacy of Multiple-dose of JS002 in Subject With Hyperlipidemia

Interventional Phase III clinical trial protocol NCT04781114 sponsored by Shanghai Junshi Bioscience Co in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-12-23 Enrollment: 806 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04781114
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)806 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04781114
Protocol FieldVerified Registry Value
NCT IdentifierNCT04781114
Consolidated Lead SponsorShanghai Junshi Bioscience Co
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment806 participants (ACTUAL)
Registered Start Date2020-12-23
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI